Amyotrophic lateral sclerosis

被引:509
作者
Mitchell, J. D. [1 ]
Borasio, G. D.
机构
[1] Royal Preston Hosp, Motor Neurone Dis Care & Res Ctr, Preston PR2 9HT, Lancs, England
[2] Munich Univ Hosp, Dept Neurol, Interdisciplinary Ctr Palliat Med, D-81366 Munich, Germany
[3] Munich Univ Hosp, Dept Neurol, Motor Neurone Dis Res Grp, D-81366 Munich, Germany
关键词
D O I
10.1016/S0140-6736(07)60944-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Amyotrophic lateral sclerosis (known in the UK as motor neuron disease) is a devastating illness with uncertain pathogenesis. In this Seminar, we review its natural history, clinical features, diagnostic criteria, variant and mimic syndromes, genetic forms, and epidemiology. Several hypotheses about causes of the disorder are discussed, such as excitotoxicity and oxidant stress, and we review past and present putative disease-modifying treatments. Disease-management strategies, from telling the patient about their illness to end-of-life decisions and palliative care, are presented. We review options for control of the main symptoms of amyotrophic lateral sclerosis-including dysphagia, dysarthria, respiratory distress, pain, and psychological disorders-and care in the terminal phase. The need for good psychosocial and spiritual care of patients and families is emphasised. We conclude with an overview of some current major issues and future prospects, ranging from the search for disease markers to challenging developments such as stem-cell and gene therapy.
引用
收藏
页码:2031 / 2041
页数:11
相关论文
共 117 条
[1]   THE ROLE OF CALCIUM-BINDING PROTEINS IN SELECTIVE MOTONEURON VULNERABILITY IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].
ALEXIANU, ME ;
HO, BK ;
MOHAMED, AH ;
LABELLA, V ;
SMITH, RG ;
APPEL, SH .
ANNALS OF NEUROLOGY, 1994, 36 (06) :846-858
[2]   Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene [J].
Andersen, Peter M. .
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2006, 6 (01) :37-46
[3]   EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives - An evidence-based review with good practice points [J].
Andersen, PM ;
Borasio, GD ;
Dengler, R ;
Hardiman, O ;
Kollewe, K ;
Leigh, PN ;
Pradat, PF ;
Silani, V ;
Tomik, B .
EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (12) :921-938
[4]  
Aoki Shigeki, 2005, Radiat Med, V23, P195
[5]  
APPEL SH, 2004, AMYOTROPH LATERAL S2, V5, P54
[6]   A RATING-SCALE FOR AMYOTROPHIC-LATERAL-SCLEROSIS - DESCRIPTION AND PRELIMINARY EXPERIENCE [J].
APPEL, V ;
STEWART, SS ;
SMITH, G ;
APPEL, SH .
ANNALS OF NEUROLOGY, 1987, 22 (03) :328-333
[7]   An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis [J].
Armon, C .
NEUROEPIDEMIOLOGY, 2003, 22 (04) :217-228
[8]   Environmental risk factors for amyotrophic lateral sclerosis [J].
Armon, C .
NEUROEPIDEMIOLOGY, 2001, 20 (01) :2-6
[9]   VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model [J].
Azzouz, M ;
Ralph, GS ;
Storkebaum, E ;
Walmsley, LE ;
Mitrophanous, KA ;
Kingsman, SM ;
Carmeliet, P ;
Mazarakis, ND .
NATURE, 2004, 429 (6990) :413-417
[10]   Mitochondrial involvement in amyotrophic lateral sclerosis - Trigger or target? [J].
Bacman, SR ;
Bradley, WG ;
Moraes, CT .
MOLECULAR NEUROBIOLOGY, 2006, 33 (02) :113-131